Drugs used in psychiatry causing an increase in body weight in children—a review

Medici V, McClave SA, Miller KR. Common medications which lead to unintended alterations in weight gain or organ lipotoxicity. Curr Gastroenterol Rep. 2016;18:2 https://doi.org/10.1007/s11894-015-0479-4.

Article 
PubMed 

Google Scholar 

Verhaegen AA, Van Gaal LF. Drugs that affect body weight, body fat distribution, and metabolism. In: Feingold KR, Anawalt B, Blackman MR, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000.

Tkacz J, Brady BL. Increasing rate of diagnosed childhood mental illness in the United States: incidence, prevalence and costs. Public Health Pr Oxf Engl. 2021;2:100204. https://doi.org/10.1016/j.puhip.2021.100204.

Article 

Google Scholar 

Racine N, McArthur BA, Cooke JE, Eirich R, Zhu J, Madigan S. Global prevalence of depressive and anxiety symptoms in children and adolescents during COVID-19: a meta-analysis. JAMA Pediatr. 2021;175:1142–50. https://doi.org/10.1001/jamapediatrics.2021.2482.

Article 
PubMed 

Google Scholar 

Lee J. Mental health effects of school closures during COVID-19. Lancet Child Adolesc Health 2020;4:421. https://doi.org/10.1016/S2352-4642(20)30109-7.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Takahashi F, Honda H. Prevalence of clinical-level emotional/behavioral problems in schoolchildren during the coronavirus disease 2019 pandemic in Japan: a prospective cohort study. JCPP Adv. 2021;1:e12007. https://doi.org/10.1111/jcv2.12007.

Article 
PubMed 
PubMed Central 

Google Scholar 

Moulin F, Bailhache M, Monnier M, Thierry X, Vandentorren S, Côté SM, et al. Longitudinal impact of psychosocial status on children’s mental health in the context of COVID-19 pandemic restrictions. Eur Child Adolesc Psychiatry. 2023;32:1073–82. https://doi.org/10.1007/s00787-022-02010-w.

Article 
PubMed 

Google Scholar 

de Onis M, Blössner M, Borghi E. Global prevalence and trends of overweight and obesity among preschool children. Am J Clin Nutr. 2010;92:1257–64. https://doi.org/10.3945/ajcn.2010.29786.

Article 
CAS 
PubMed 

Google Scholar 

Kuźbicka K, Rachoń D. Bad eating habits as the main cause of obesity among children. Pediatr Endocrinol Diabetes Metab. 2013;19:106–10.

PubMed 

Google Scholar 

Dietz WH. Health consequences of obesity in youth: childhood predictors of adult disease. Pediatrics 1998;101:518–25.

Article 
CAS 
PubMed 

Google Scholar 

Griffiths LJ, Dezateux C, Hill A. Is obesity associated with emotional and behavioural problems in children? Findings from the millennium cohort study. Int J Pediatr Obes IJPO J Int Assoc Study Obes. 2011;6:e423–432. https://doi.org/10.3109/17477166.2010.526221.

Article 

Google Scholar 

Kelsey MM, Zaepfel A, Bjornstad P, Nadeau KJ. Age-related consequences of childhood obesity. Gerontology. 2014;60:222–8. https://doi.org/10.1159/000356023.

Article 
PubMed 

Google Scholar 

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71 https://doi.org/10.1136/bmj.n71.

Article 
PubMed 
PubMed Central 

Google Scholar 

Jahangard L, Akbarian S, Haghighi M, Ahmadpanah M, Keshavarzi A, Bajoghli H, et al. Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed—results from a randomized, double-blind, placebo-controlled clinical trial. Psychiatry Res. 2017;251:182–91. https://doi.org/10.1016/j.psychres.2016.12.010.

Article 
CAS 
PubMed 

Google Scholar 

Ceylan MF, Erdogan B, Tural Hesapcioglu S, Cop E. Effectiveness, adverse effects and drug compliance of long-acting injectable risperidone in children and adolescents. Clin Drug Investig. 2017;37:947–56. https://doi.org/10.1007/s40261-017-0555-7.

Article 
CAS 
PubMed 

Google Scholar 

Gagliano A, Germanò E, Pustorino G, Impallomeni C, D’Arrigo C, Calamoneri F, et al. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J Child Adolesc Psychopharmacol. 2004;14:39–47. https://doi.org/10.1089/104454604773840472.

Article 
PubMed 

Google Scholar 

Jedrzejczak J, Kuncíková M, Magureanu S. An observational study of first-line valproate monotherapy in focal epilepsy. Eur J Neurol. 2008;15:66–72. https://doi.org/10.1111/j.1468-1331.2007.02003.x.

Article 
CAS 
PubMed 

Google Scholar 

Savitz AJ, Lane R, Nuamah I, Gopal S, Hough D. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. J Am Acad Child Adolesc Psychiatry. 2015;54:126–137.e1. https://doi.org/10.1016/j.jaac.2014.11.009.

Article 
PubMed 

Google Scholar 

Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet Lond Engl. 1999;354:13–9. https://doi.org/10.1016/s0140-6736(98)10531-7.

Article 
CAS 

Google Scholar 

Fraguas D, Merchán-Naranjo J, Laita P, Parellada M, Moreno D, Ruiz-Sancho A, et al. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry. 2008;69:1166–75. https://doi.org/10.4088/jcp.v69n0717.

Article 
CAS 
PubMed 

Google Scholar 

Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, et al. Double-blind maintenance safety and effectiveness findings from the treatment of early-onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry. 2010;49:583–94. https://doi.org/10.1016/j.jaac.2010.03.013.

Article 
PubMed 
PubMed Central 

Google Scholar 

Jensen KG, Correll CU, Rudå D, Klauber DG, Decara MS, Fagerlund B, et al. Cardiometabolic adverse effects and its predictors in children and adolescents with first-episode psychosis during treatment with quetiapine-extended release versus aripiprazole: 12-week results from the tolerance and effect of antipsychotics in children and adolescents with psychosis (TEA) trial. J Am Acad Child Adolesc Psychiatry. 2019;58:1062–78. https://doi.org/10.1016/j.jaac.2019.01.015.

Article 
PubMed 

Google Scholar 

Ghaleiha A, Mohammadi E, Mohammadi MR, Farokhnia M, Modabbernia A, Yekehtaz K, et al. Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. Paediatr Drugs. 2013;15:505–14. https://doi.org/10.1007/s40272-013-0036-2.

Article 
PubMed 

Google Scholar 

Fleischhaker C, Heiser P, Hennighausen K, Herpertz-Dahlmann B, Holtkamp K, Mehler-Wex C, et al. Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol. 2006;16:308–16. https://doi.org/10.1089/cap.2006.16.308.

Article 
PubMed 

Google Scholar 

Pavuluri MN, Henry DB, Findling RL, Parnes S, Carbray JA, Mohammed T, et al. Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Disord. 2010;12:593–605. https://doi.org/10.1111/j.1399-5618.2010.00850.x.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, DeThomas C, Cullen K, et al. Clozapine versus “high-dose” olanzapine in refractory early-onset schizophrenia: an open-label extension study. J Child Adolesc Psychopharmacol. 2008;18:307–16. https://doi.org/10.1089/cap.2007.0089.

Article 
PubMed 
PubMed Central 

Google Scholar 

Detke HC, DelBello MP, Landry J, Usher RW. Olanzapine/Fluoxetine combination in children and adolescents with bipolar I depression: a randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2015;54:217–24. https://doi.org/10.1016/j.jaac.2014.12.012.

Article 
PubMed 

Google Scholar 

Pagsberg AK, Jeppesen P, Klauber DG, Jensen KG, Ruda D, Stentebjerg-Olesen M, et al. Quetiapine extended release versus aripiprazole in children and adolescents with first-episode psychosis: the multicentre, double-blind, randomised tolerability and efficacy of antipsychotics (TEA) trial. Lancet Psychiatry. 2017;4:605–18. https://doi.org/10.1016/S2215-0366(17)30166-9.

Article 
PubMed 

Google Scholar 

Biton V, Levisohn P, Hoyler S, Vuong A, Hammer AE. Lamotrigine versus valproate monotherapy-associated weight change in adolescents with epilepsy: results from a post hoc analysis of a randomized, double-blind clinical trial. J Child Neurol. 2003;18:133–9. https://doi.org/10.1177/08830738030180021701.

Article 
PubMed 

Google Scholar 

Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA. 2009;302:1765–73. https://doi.org/10.1001/jama.2009.1549.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Ondo WG, Jong D, Davis A. Comparison of weight gain in treatments for Tourette syndrome: tetrabenazine versus neuroleptic drugs. J Child Neurol. 2008;23:435–7. https://doi.org/10.1177/0883073807307108.

Article 
PubMed 

Google Scholar 

Arango C, Buitelaar JK, Fegert JM, Olivier V, Penelaud PF, Mrx U, et al. Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries. Lancet Psychiatry. 2022;9:113–24. https://doi.org/10.1016/S2215-0366(21)00390-4.

Article 
PubMed 

Google Scholar 

Findling RL, Robb A, McNamara NK, Pavuluri MN, Kafantaris V, Scheffer R, et al. Lithium in the acute treatment of bipolar I disorder: a double-blind, placebo-controlled study. Pediatrics. 2015;136:885–94. https://doi.org/10.1542/peds.2015-0743.

Article 
PubMed 
PubMed Central 

Google Scholar 

Findling RL, McNamara NK, Pavuluri M, Frazier JA, Rynn M, Scheffer R, et al. Lithium for the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled discontinuation study. J Am Acad Child Adolesc Psychiatry. 2019;58:287–.e4. https://doi.org/10.1016/j.jaac.2018.07.901.

Article 
PubMed 

Google Scholar 

Haas M, Delbello MP, Pandina G, Kushner S, Van Hove I, Augustyns I, et al. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2009;11:687–700. https://doi.org/10.1111/j.1399-5618.2009.00750.x.

Article 
CAS 
PubMed 

Google Scholar 

Reyes M, Buitelaar J, Toren P, Augustyns I, Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry. 2006;163:402–10. https://doi.org/10.1176/appi.ajp.163.3.402.

Article 
PubMed 

Google Scholar 

Buitelaar JK, van der Gaag RJ, Cohen-Kettenis P, Melman CT. A randomized controlled trial of risperidone in the treatment of aggression in hospitalized adolescents with subaverage cognitive abilities. J Clin Psychiatry. 2001;62:239–48. https://doi.org/10.4088/jcp.v62n0405.

Article 
CAS 
PubMed 

Google Scholar 

Rao WW, Zong QQ, Zhang JW, An FR, Jackson T, Ungvari GS, et al. Obesity increases the risk of depression in children and adolescents: results from a systematic review and meta-analysis. J Affect Disord. 2020;267:78–85. https://doi.org/10.1016/j.jad.2020.01.154.

Article 
PubMed 

Google Scholar 

Ells LJ, Lang R, Shield JPH, Wilkinson JR, Lindstone JSM, Coulton S, et al. Obesity and disability—a short review. Obes Rev J Int Assoc Study Obes. 2006;7:341–5. https://doi.org/10.1111/j.1467-789X.2006.00233.x.

Article 
CAS 

Google Scholar 

Koskentausta T, Iivanainen M, Almqvist F. Psychiatric disorders in children with intellectual disability. Nord J Psychiatry. 2002;56:126–31. https://doi.org/10.1080/080394802753617944.

Article 
PubMed 

Google Scholar 

Slevin E, Truesdale-Kennedy M, McConkey R, Livingstone B, Fleming P. Obesity and overweight in intellectual and non-intellectually disabled children. J Intellect Disabil Res JIDR. 2014;58:211–20. https://doi.org/10.1111/j.1365-2788.2012.01615.x.

Article 
CAS 
PubMed 

Google Scholar 

Emerson E, Robertson J, Baines S, Hatton C. Obesity in British children with and without intellectual disability: cohort study. BMC Public Health. 2016;16:644 https://doi.org/10.1186/s12889-016-3309-1.

Article 
PubMed 
PubMed Central 

Google Scholar 

Choi E, Park H, Ha Y, Hwang WJ. Prevalence of overweight and obesity in children with intellectual disabilities in Korea. J Appl Res Intellect Disabil JARID. 2012;25:476–83. https://doi.org/10.1111/j.1468-3148.2012.00694.x.

Article 
PubMed 

Google Scholar 

Yuan YQ, Liu Y, Wang MJ, Hou X, Zhang SH, Wang XL, et al. Prevalence of overweight and obesity in children and adolescents with intellectual disabilities in China. J Intellect Disabil Res JIDR. 2021;65:655–65. https://doi.org/10.1111/jir.12840.

Article 
CAS 
PubMed 

Google Scholar 

Maïano C, Hue O, Morin AJS, Moullec G. Prevalence of overweight and obesity among children and adolescents with intellectual disabilities: a systematic review and meta-analysis. Obes Rev J Int Assoc Study Obes. 2016;17:599–611. https://doi.org/10.1111/obr.12408.

Article 

Google Scholar 

Wiedeman AM, Panagiotopoulos C, Devlin AM. Treatment-related weight gain and metabolic complications in children with mental health disorders: potential role for lifestyle interventions. Appl Physiol Nutr Metab Physiol Appl Nutr Metab. 2021;46:193–204. https://doi.org/10.1139/apnm-2020-0259.

Article 

Google Scholar 

Martínez-Ortega JM, Funes-Godoy S, Díaz-Atienza F, Gutiérrez-Rojas L, Pérez-Costillas L, Gurpegui M. Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry. 2013;22:457–79. https://doi.org/10.1007/s00787-013-0399-5.

Article 
PubMed 

Google Scholar 

Libowitz MR, Nurmi EL. The burden of antipsychotic-induced weight gain and metabolic syndrome in children. Front Psychiatry. 2021;12:623681. https://doi.org/10.3389/fpsyt.2021.623681.

Article 
PubMed 
PubMed Central 

Google Scholar 

Lifshitz F. Obesity in children. J Clin Res Pediatr Endocrinol. 2008;1:53–60. https://doi.org/10.4008/jcrpe.v1i2.35.

Article 
PubMed 
PubMed Central 

Google Scholar 

Bégarie J, Maïano C, Leconte P, Ninot G. The prevalence and determinants of overweight and obesity among French youths and adults with intellectual disabilities attending special education schools. Res Dev Disabil. 2013;34:1417–25. https://doi.org/10.1016/j.ridd.2012.12.007.

Article 
PubMed 

Google Scholar 

Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64–77. https://doi.org/10.1016/S2215-0366(19)30416-X.

Article 
PubMed 
PubMed Central 

Google Scholar 

Correll CU. Addressing adverse effects of antipsychotic treatment in young patients with schizophrenia. J Clin Psychiatry. 2011;72:e01 https://doi.org/10.4088/JCP.9101tx6c.

Article 
PubMed 

Google Scholar 

Safer DJ. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol. 2004;24:429–36. https://doi.org/10.1097/01.jcp.0000130558.86125.5b.

Article 
CAS 
PubMed 

Google Scholar 

Nehme H, Saulnier P, Ramadan AA, Cassisa V, Guillet C, Eveillard M, et al. Antibacterial activity of antipsychotic agents, their association with lipid nanocapsules and its impact on the properties of the nanocarriers and on antibacterial activity. PloS ONE. 2018;13:e0189950 https://doi.org/10.1371/journal.pone.0189950.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Yuan X, Zhang P, Wang Y, Liu Y, Li X, Kumar BU, et al. Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia. Schizophr Res. 2018;201:299–306. https://doi.org/10.1016/j.schres.2018.05.017.

Article 
PubMed 

Google Scholar 

Ait Chait Y, Mottawea W, Tompkins TA, Hammami R. Unravelling the antimicrobial action of antidepressants on gut commensal microbes. Sci Rep. 2020;10:17878 https://doi.org/10.1038/s41598-020-74934-9.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Ignacio A, Fernandes MR, Rodrigues VAA, Groppo FC, Cardoso AL, Avila-Campos MJ, et al. Correlation between body mass index and faecal microbiota from children. Clin Microbiol Infect Publ Eur Soc Clin Microbiol Infect Dis. 2016;22:258–e1-8. https://doi.org/10.1016/j.cmi.2015.10.031.

Article 

Google Scholar 

Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28:203–9.

PubMed 
PubMed Central 

Google Scholar 

Huang J, Hei GR, Yang Y, Liu CC, Xiao JM, Long YJ, et al. Increased appetite plays a key role in olanzapine-induced weight gain in first-episode schizophrenia patients. Front Pharm. 2020;11:739. https://doi.org/10.3389/fphar.2020.00739.

Article 
CAS 

Google Scholar 

Chen H, Cao T, Zhang B, Cai H. The regulatory effects of second-generation antipsychotics on lipid metabolism: potential mechanisms mediated by the gut microbiota and therapeutic implications. Front Pharm. 2023;14:1097284. https://doi.org/10.3389/fphar.2023.1097284.

Article 
CAS 

Google Scholar 

Endomba FT, Tankeu AT, Nkeck JR, Tochie JN. Leptin and psychiatric illnesses: does leptin play a role in antipsychotic-induced weight gain? Lipids Health Dis. 2020;19:22 https://doi.org/10.1186/s12944-020-01203-z.

Article 
PubMed 
PubMed Central 

Google Scholar 

Fan Z, Wu Y, Shen J, Ji T, Zhan R. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res. 2013;47:1549–56. https://doi.org/10.1016/j.jpsychires.2013.07.011.

Article 
PubMed 

Google Scholar 

Abenavoli L, Scarpellini E, Colica C, Boccuto L, Salehi B, Sharifi-Rad J, et al. Gut microbiota and obesity: a role for probiotics. Nutrients. 2019;11. https://doi.org/10.3390/nu11112690.

Balanzá Martínez V. Nutritional supplements in psychotic disorders. Actas Esp Psiquiatr. 2017;45:16–25.

PubMed 

Google Scholar 

Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord Int Epilepsy J Videotape. 2015;17:117–23. https://doi.org/10.1684/epd.2015.0736.

Article 

Google Scholar 

Verrotti A, D’Egidio C, Mohn A, Coppola G, Chiarelli F. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev J Int Assoc Study Obes. 2011;12:e32–43. https://doi.org/10.1111/j.1467-789X.2010.00800.x.

Article 
CAS 

Google Scholar 

Howard JK, Flier JS. Attenuation of leptin and insulin signaling by SOCS proteins. Trends Endocrinol Metab Tem. 2006;17:365–71. https://doi.org/10.1016/j.tem.2006.09.007.

Article 
CAS 
PubMed 

Google Scholar 

Brown R, Imran SA, Ur E, Wilkinson M. Valproic acid and CEBPalpha-mediated regulation of adipokine gene expression in hypothalamic neurons and 3T3-L1 adipocytes. Neuroendocrinology. 2008;88:25–34. https://doi.org/10.1159/000113927.

Article 
CAS 
PubMed 

Google Scholar 

Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand. 1984;70:65–69. https://doi.org/10.1111/j.1600-0404.1984.tb00804.x.

Article 
CAS 
PubMed 

Google Scholar 

Espinosa PS, Salazar JC, Yu L, Mendiondo MS, Robertson WC, Baumann RJ. Lack of valproic acid-associated weight gain in prepubertal children. Pediatr Neurol. 2008;39:177–80. https://doi.org/10.1016/j.pediatrneurol.2008.05.006.

Article 
PubMed 

Google Scholar 

Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, McGuire H, et al. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: systematic review and meta-analysis. CNS Drugs. 2010;24:35–53. https://doi.org/10.2165/11319480-000000000-00000.

Article 
CAS 
PubMed 

Google Scholar 

Lechner K, Heel S, Uhr M, Dose T, Holsboer F, Lucae S, et al. Weight-gain independent effect of mirtazapine on fasting plasma lipids in healthy men. Naunyn Schmiedebergs Arch Pharm. 2023;396:1999–2008. https://doi.org/10.1007/s00210-023-02448-y.

Article 
CAS 

Google Scholar 

Selph SS, McDonagh MS. Depression in children and adolescents: evaluation and treatment. Am Fam Physician. 2019;100:609–17.

PubMed 

Google Scholar 

Greil W, de Bardeci M, Müller-Oerlinghausen B, Nievergelt N, Stassen H, Hasler G, et al. Controversies regarding lithium-associated weight gain: case-control study of real-world drug safety data. Int J Bipolar Disord. 2023;11:34 https://doi.org/10.1186/s40345-023-00313-8.

Article 
CAS 
PubMed 
PubMed Central 

Google Scholar 

Mozes T, Greenberg Y, Spivak B, Tyano S, Weizman A, Mester R. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study. J Child Adolesc Psychopharmacol. 2003;13:311–7. https://doi.org/10.1089/104454603322572642.

Article 
PubMed 

Google Scholar 

Redden L, DelBello M, Wagner KD, Wilens TE, Malhotra A, Wozniak P, et al. Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder. J Child Adolesc Psychopharmacol. 2009;19:83–89. https://doi.org/10.1089/cap.2008.0106.

Article 
PubMed 

Google Scholar 

Findling RL, Groark J, Tourian KA, Ramaker SA, Chiles D, Yang L, et al. Pharmacokinetics and tolerability of single-ascending doses of desvenlafaxine administered to children and adolescents with major depressive disorder. J Child Adolesc Psychopharmacol. 2016;26:909–21. https://doi.org/10.1089/cap.2016.0009.

Article 
CAS 
PubMed 

Google Scholar 

Jan MMS, Zuberi SA, Alsaihati BA. Pregabalin: preliminary experience in intractable childhood epilepsy. Pediatr Neurol. 2009;40:347–50. https://doi.org/10.1016/j.pediatrneurol.2008.12.016.

Article 
PubMed 

Google Scholar 

Mrakotsky C, Masek B, Biederman J, Raches D, Hsin O, Forbes P, et al. Prospective open-label pilot trial of mirtazapine in children and adolescents with social phobia. J Anxiety Disord. 2008;22:88–97. https://doi.org/10.1016/j.janxdis.2007.01.005.

Article 
PubMed 

Google Scholar 

Heck A, Holleman A. Growth of Dutch Children. Presented at: 2001; AMSTEL Institute; available at: https://staff.fnwi.uva.nl/a.j.p.heck/research/growth/taskA.pdf.

Israel EJ, Levitsky LL, Anupindi SA, Pitman MB. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 3-2005. A 14-year-old boy with recent slowing of growth and delayed puberty. N. Engl J Med. 2005;352:393–403. https://doi.org/10.1056/NEJMcpc049032.

Article 
CAS 
PubMed 

Google Scholar